EPRX (Eupraxia Pharmaceuticals Inc.) Stock | Pipeline ...
Analyze Eupraxia Pharmaceuticals Inc. (EPRX) stock. View upcoming FDA catalysts, clinical trial data, real-time insider trades, and hedge fund holdings. Updated for 2026.
Eupraxia's Equity Raise: Assessing the Capital Allocation and ...
Feb 19, 2026 · The capital raise secures the runway, but the valuation will be tested by the clinical data and operational execution that follow. Each of these catalysts provides a discrete checkpoint to …
EUPRAXIA PHARMACEUTICALS INC. (EPRX) 2026 40-F Annual Report ...
Based on its current spending rate, the company estimates it has enough cash to operate for approximately 12-15 months. This indicates a need for future financing to sustain operations through …
Eupraxia Pharmaceuticals (EPRX) Stock Price & Overview
1 day ago · A detailed overview of Eupraxia Pharmaceuticals Inc. (EPRX) stock, including real-time price, chart, key statistics, news, and more.
Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI ...
Sam Slutsky has given his Buy rating due to a combination of factors related to Eupraxia’s lead asset and financial position.
Biotech Eupraxia Doses First Patient in Phase 2b EoE Drug ...
Aug 12, 2025 · Clinical-stage biotech advances EP-104GI treatment for eosinophilic esophagitis with positive 9-month data and Phase 2b trial initiation. $19.8M cash runway into Q3 2026. See details.
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 ...
Detailed price information for Eupraxia Pharmaceuticals Inc (EPRX-Q) from The Globe and Mail including charting and trades.